The upstream cell culture sector has seen expansion activity recently as some contract biomanufacturers invest in their cell culture facilities. Major projects announced in the past year include Lonza’s new Ibex solutions that the company is building in Visp, Switzerland, to support multiple technologies, including monoclonal antibody (mAb) cell culture, and FUJIFILM Diosynth Biotechnologies’ new cell culture laboratories in Teesside, UK, among others. Click Here For Complete Abstract Text
|
|||||||||||||||||||||||||||
| Application Sequencing | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||||||